Latest Articles

Publication Date
Glypican3 and serglycin as potential biomarkers involved in the pathogenesis of ovarian endometriosis.

Endometriosis, a non-malignant gynecological disorder characterized by debilitating symptoms, displays several cancer-like characteristics, including metastatic behavior and extracellular matrix (ECM) remodeling. The dynamics of ECM are largely influenced by proteoglycans …

Published: March 20, 2025, midnight
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - The Malaysian Reserve

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy The Malaysian …

Published: March 19, 2025, 10:53 p.m.
AI model detects endometrial cancer at almost 100 per cent accuracy - NT News

AI model detects endometrial cancer at almost 100 per cent accuracy NT News

Published: March 19, 2025, 3:45 p.m.
Canada Approves KEYTRUDA For Advanced Endometrial Cancer - Evrim Ağacı

Canada Approves KEYTRUDA For Advanced Endometrial Cancer Evrim Ağacı

Published: March 19, 2025, 2:55 p.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Weekly Voice

Published: March 19, 2025, 11:20 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Canada …

Published: March 19, 2025, 11 a.m.
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Finance

Published: March 19, 2025, 11 a.m.
Investigational ADC Shows Promise in Advanced Endometrial Cancer - MSN

Investigational ADC Shows Promise in Advanced Endometrial Cancer MSN

Published: March 19, 2025, 1:18 a.m.
Analysis of risk factors for recurrence after laparoscopic myomectomy: A retrospective study.

At present, there is unclear on the risk factors of recurrence after myomectomy. In this study, we hope to provide reference for the choice of treatment for patients with uterine …

Published: March 19, 2025, 12:17 a.m.
Investigational ADC Shows Promise in Advanced Endometrial Cancer - Medpage Today

Investigational ADC Shows Promise in Advanced Endometrial Cancer Medpage Today

Published: March 18, 2025, 8:07 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!